Page 656«..1020..655656657658..670680..»

Can we bring back the woolly mammoth? – The Indian Express

Posted: October 5, 2021 at 8:10 pm

The team of scientists led by George Church, a geneticist at Harvard Medical School, will use genetic engineering to develop a cold-resistant elephant or an Arctic elephant. Several news reports have pointed out that the company has received $15 million in initial funding.

The team has selected over 50 traits that will enhance the cold-resistant ability of an Asian elephant. These include shaggy coats, smaller ears, cold-adapted forms of haemoglobin and excess adipose tissue production.

The idea is to use these genes and with the help of CRISPR technology insert them into the Asian elephants genome. The team will then create an embryo that carries the traits of a woolly mammoth.

The embryo will be implanted into a surrogate African elephant. The gestation in the elephants womb will take place for around 18-22 months and a hybrid Arctic elephant will be born.

But why a woolly mammoth and why now?

Colossal mentions on its website that one of the core goals for reviving the mammoth is to revert the now-overshrubbed forests into natural arctic grasslands, which will help with carbon emissions.

The tundra, which is now a mossy forest, used to be a grassland and the team said that bringing back the mammoths could help bring back the steppe (unforested grassland) ecosystem and help in reversing the rapid warming of the climate.

They said that grazing mammoths will help re-establish the grassland ecosystem and prevent the thawing and release of greenhouse gases that are now trapped in the arctic permafrost.

Dr George Church told the IndianExpress.com that for carbon sequestration preserving the methane from being released and bringing new carbon dioxide into the frozen soil models have shown that about 100 Arctic elephants would be needed.

We would need an area of somewhere between one and three million square kilometre at first to have an impact. But considering there are about 20 million square kilometre of Arctic, thats a small fraction, he added.

When will an Arctic elephant be born?

Ben Lamm, the founder and CEO of Colossal Biosciences, told reporters that one can see the first generation of Arctic elephant calves in four to six years. Our goal is a little over a decade before we get full reintroduction, he added.

Lamm said that the short-term plan includes developing veterinary reproductive technologies for endangered species in particular, and for endangered environments and ecosystems.

Look at this like the Apollo programme. When humankind went to the moon, we actually developed a lot of great technologies, including technologies that are allowing us to have this conversation today. And so we think theres a lot of applications of the technologies that will come out of these synthetic wombs, multiplex editing which can be used for protecting critically endangered species, in agriculture, and for veterinary use, he added.

Ethical questions

Professor Adrian M Lister from the Division of Vertebrates and Anthropology at Natural History Museum London told the IndianExpress.com that this plan raises many ethical questions, Especially since we are talking about a highly intelligent, social animal, not a lab animal like a fruit fly or a nematode worm.

He added that it was quite likely that there would be many failed experiments (abortions or malformed births) before they might have a successful pregnancy and a functioning offspring.

Second, do we really know enough about the elephants adaptations to be sure we can fully equip it for life in the Arctic? This is a tropical animal that lives in equatorial daylight and climatic regime, eating trees and tall tropical grasses. They may be able to engineer a thick coat and fat layer, for example, but there may be many other necessary physiological or biochemical adaptations that we are not aware of. Will these animals thrive in such an alien environment? he asked.

Follow this link:
Can we bring back the woolly mammoth? - The Indian Express

Posted in Genetic Engineering | Comments Off on Can we bring back the woolly mammoth? – The Indian Express

Science, business and the humanities: CP Snow’s ‘Two Cultures’ sixty years on – TheArticle

Posted: October 5, 2021 at 8:10 pm

CP Snow was a Cambridge scientist, a civil servant, and a novelist. He was, therefore, well placed to observe the gap between science, on one hand, and the arts and humanities on the other hand. He named it the two cultures divide, and his observations on it, in which he lamented the divides growing extent, formed the substance of his much-discussed Rede Lecture for 1959, subsequently published as a book.

His principal anxiety was that, whereas scientists can take a knowledgeable interest in the arts and humanities, the reverse is rarely true, and this is a problem because almost everyone in government in his day, whether politicians or civil servants, tended to be arts and humanities graduates, with little understanding of science but complete control of science policy and most of its funding.

The problem Snow identified had grown out of the extraordinarily rapid expansion of scientific knowledge in the period less than a century before he delivered his lecture, while the fundamentals of elite education, predicated on the classics and humanities, had not changed much. At the date of his lecture, science subjects were still looked down upon as bangs and smells, and were lumped together with engineering and technology as the domain of nerds with dirty fingernails and rows of pens in their top pockets, a far cry from the languid cravat-wearing aesthete with a volume of Shelley in one hand and a cigarette-holder in the other.

The real problem was that the depth and complexity of science had quickly resulted in a proliferation of specialisms, sometimes not fully accessible even to specialists in neighbouring areas of the same science. Competence in any area of, say, physics required a training and possession of mathematical abilities beyond the reach of most. This is even more true today. When Snow delivered his lecture, the Standard Model of the atom was still being formulated and the development of instruments of investigation was rudimentary in comparison to now, unsurprising given that when Snow wrote it was not much more than thirty years since quantum theory had been given, what might be called, its official imprimatur at the Solvay Conference of 1927.

In one very important respect, however, Snows two cultures division was incorrect. There was, in fact, not a division between two cultures but instead a three-way split, a triangle of cultures, though the third vertex of the triangle was so far beneath notice at the time Snow wrote that rather as one would expect from an Oxbridge don of the day it did not occur to him to include it. This third vertex is business. If the humanities student looked down his nose at the science student, neither of them even noticed the student of accountancy or commerce at the College of Further Education out in the suburbs.

This was the lingering attitude of snobbery about trade that had its origin in the far distant past in the classical Greek disdain for anything banausic, for buying and selling and taking an interest in money. Pythagoras said that people fell into three classes, mirroring those at the Games: competitors, spectators, and those who came to hawk their wares under the stands. He likened philosophers to spectators; in Greek to spectate is theorein, the source of our theory. Plato was disgusted by the sophists who offered to teach, for a fee, how to make a bad argument beat a good argument.

Statue of Plato, Athens (Alamy)

The unnoticed third vertex in Snows account has since risen into great importance in the triangle. Indeed, there has been a remarkable transformation in the respectability of business; successful businessmen and women are admired, the importance of business to the national economy is fully recognised, the wealth of top business people has risen hugely and given them significant influence in society and politics. Things had long been different in the US; there, money-making from business had been admired and encouraged at least since the years following the Civil War. In the unrestrained conditions of the expanding frontier and its abundant resources, together with a flow of both skilled and cheap labour through immigration, business millionaires became Americas aristocracy. That was still not the case in Snows Britain at the time he wrote. In the following decades it has become so; and it has radically changed the cultures divide he described.

It is still the case that few people can say what the Second Law of Thermodynamics is, which was Snows challenge to those who complained that scientists do not read poetry. But business entrepreneurs were not slow to recognise and profit from the scientific and technological advances which have transformed the world over the last half-century. It has made many of them rich, and they fuel the digital revolution by their energetic desire to see faster, smaller, more powerful, more capable technologies operative in many areas of activity. Meanwhile science genetics, biochemistry, neuroscience, particle physics, cosmology has continued to race ahead and astonish, with its applications via technology already outstripping our ability to manage its impacts (think of the potential downsides, along with the upsides, of artificial intelligence, genetic engineering, brain-chip interfaces, military robots, and the like).

The alliance between science and business and the prominence of both explains why the two areas of greatest pull in higher education are STEM subjects science, technology, engineering and mathematics and business studies. Between them they are the culturally dominant elements of the triangle, when in Snows day this role had been occupied by the humanities. In consequence, the humanities are withering. Parents and school advisers, together with the facts of life about what todays economies need in the way of skilled workforces, between them push and pull students into STEM or business studies in large and increasing numbers. In some universities the study of modern languages, literature, history and philosophy has vanished altogether; classics vanished from almost all universities long ago. The forces at work are Darwinian, and understandable.

You might cite the immortal words of Mandy Rice-Davies, He would say that, wouldnt he, in response to what I as a lifelong student of the humanities, and founder of a university college called New College of the Humanities (now part of Northeastern University) am about to say here. But note the concluding sentence of the preceding paragraph: I acknowledge the Darwinian imperatives, and do not propose to argue for a reassertion of the situation prevailing in Snows day. But allow me to recount an anecdote that explains why concentrating just on two vertices of the triangle at the expense of the third humanities is a mistake; as follows.

When Ronald Reagan was President he proposed that the US should develop an anti-ballistic missile system based on satellites in earth orbit the so-called Star Wars initiative so that an attack on the US by the Soviet Union could be interdicted in space. It eventually transpired that the suggestion was merely a propaganda device to turn the screws on the Soviet Union; there was, it seems, no real prospect of such a system being created. In the anxious debate that the suggestion prompted, however, one withering contribution was made by the physicist Steven Weinberg (pictured below, centre), who had won the Nobel prize for his contribution to showing how the weak nuclear force, responsible for radioactive decay in atomic nuclei, can be combined with the electromagnetic force that governs interactions between charged particles, thus yielding the electroweak force. He said (I paraphrase): It does not bother me that the President doesnt know any physics, but it does bother me that he doesnt know any history or philosophy, because if he did he would not dream of increasing tensions in the Cold War in this way.

Queen Beatrix with Christian de Duve and Steven Weinberg (centre)(Alamy)

This is a telling remark. History and philosophy and one might add literature, languages, the arts give us the insights, the overview, the understanding of human nature and the human condition, and with them the experiential and ethical dimensions of both individual and social existence, that provide context for how we use science, how we do business, how we direct public policy, and most importantly, why we do what we do in these respects. Weinbergs point concerned the larger human and social context, exactly the subject matter of historical and philosophical reflection.

The lessons learned in study of the humanities can be richly suggestive. Consider history: the Bronze Age Collapse around 1200 BCE was in significant part the result of disruption of supply chains, destroying economies and the political structures based on them. The French Revolution had, as a major cause, the social and economic injustices felt by those at the wrong end of a too great rich-poor gap. Personality politics rarely end well, from Caesar to Ceausescu. And so on. All three examples carry hints for very present discontents in our world.

Consider philosophy: ideas, beliefs, ideologies are the springs that vitalise society. Examining them and their implications, challenging them, exploring what is really at stake in this -ism or that, postulating fresh ways of thinking and seeing, are essential to a civilisations health. Think of what happens when an orthodoxy is imposed by force, and only one set of ideas is permitted and no discussion allowed, as in Kims North Korea. Think of the stagnation of any society under the heel of a monolithic ideology; history offers plenty of examples.

Consider literature: the stories we tell in novels, plays, poems, the cinema, are a million windows into human experience and feeling, extending our capacity if we are attentive to understand and sympathise with the variety in human motivation and to become acquainted with choices, perceptions, attitudes, ways of life, that we would not otherwise encounter. The same applies to learning languages, to appreciating the arts, to becoming receptive and perceptive as a result of being transported over the landscapes of human experience by all these expressive, communicative enterprises.

To become a research scientist, a chemical engineer, a financial advisor, one needs training. The complexities of science and business demand specialisation. A training is essential if one is to be successful in most of these fields. Therefore, training is important. But training is not education, and as the foregoing remarks show, what the humanities offer is education: the nourishing, equipping and expanding of mind and its capacities.

Oddly enough, a survey of what a complex modern economy requires shows that many of its arenas require precisely the sensibility that the arts and humanities offer to develop. They include journalism, politics, law, the civil service, creative industries, publishing, advertising, arts promotion and management, events, entertainment, human resources, education, performance, museology and curating, design, the tourism and hospitality industries, many aspects of retail, and more the list is long.

And this is to leave aside one enormously important point that most thinking about training and education ignores, with the result that the idea of education for its own sake has so significantly diminished. This is that people are not only their careers; they are not only infantry on the economic battlefield. They are also spouses, parents, voters, travellers, lovers, gardeners, readers, neighbours, dreamers, consumers, tennis players, cinema-goers, and much else again life is many things, and being awake to its variety and its possibilities requires much more equipment than just a training for a specific career.

My idea in founding the New College of the Humanities was to make a statement about two things: the importance of the humanities, and the fact that they can and should be combined with a full acknowledgment of the importance in our time of the other two vertices of the triangle, STEM and business. So I made it a requirement that throughout their undergraduate studies in the humanities my students take, for an additional diploma, courses in science literacy so that they would have an intelligent laypersons overview of the main developments in science and basic business studies, equipping them to understand entrepreneurship, the essentials of marketing, how to read a balance sheet, what is required in the world of work, and general financial literacy. In a world now so dependent on digital technologies, literacy and competence in these is a necessity too.

The thought was that the demand for appropriate preparation for life after formal education should not entirely displace the opportunity to explore ideas, the past and literature, but that what the humanities offer should be recognised as of great value in itself, and can readily be combined with practical considerations. Education and training do not have to be mutually exclusive. My design was to provide the opportunity for the humanities intellectual maturation and fertilisation, with an adjunct of practical knowledge, to overcome the false dichotomy of the two.

It is a principle of education viewed as the cultivation of a well-furnished and highly able mind that the beneficiary of it should develop a rich sense of context and connection. Someone interested in, say, medieval monasticism or Presocratic philosophy might relish the study of it for its own sake and find it absorbingly interesting, but might also see surprising relevances to his own life and times. This explains how, in the 18th and 19th centuries, Britain governed an empire by teaching Greek and Latin classics to those sent out to run it. For when you read and discuss the classics you read history, philosophy and literature, and through them you read about and discuss government, military affairs, ideas of justice and morality, statesmen and the way they handled problems, successes and disasters and what prompted either, subtleties of human nature, celebrations of virtue and condemnations of vice, poems of love and of mourning, the absurdity of certain beliefs, the nobility of certain ambitions and much besides of relevance to both the social and individual scales of life.

Of course, much of this might have gone over most of the heads of lazy and self-interested boys at their public schools we see an example of this vividly in our own day, alas but enough stuck so that the administration of empire was not always and everywhere a prejudiced and exploitative disaster. In any case, the point is that the aim of imparting the benefits of an education in the humanities might succeed often enough that the candles of civilisation will continue be carried, alight, over the floodwaters of time. Even if almost every educational institution should shed its commitment to the humanities, salvation would reside in that almost.

There might be another spin of the triangles orientation which changes which vertex is uppermost. Suppose most productive activity is taken over by artificial intelligence systems, with the result that more than enough wealth is generated to allow most of the population a comfortable national wage without having to work for a living. Then the arts and humanities will be at a premium, the practice and study of them the main avocation of many, the value of intellectual and educational attainment as great as the value of money-wealth is now. It is far from an impossibility that this might happen. It would be good if a flourishing tradition of the humanities were to survive into such a time.

CP Snow wished to see the two cultures divide closed, or at least narrowed. I say that that the three vertices of the triangle should be kept connected, because to lose the perspectives offered by the humanities would render our society technocratic and banausic merely, a fate it is already not far from. Snows anxiety was that science would be mishandled by uncomprehending humanists, whereas today the anxiety is very different; it is that technology and the imperatives of bottom lines will determine all our choices for us.

Perhaps one can sum up the matter by saying that whereas science and technology is about capability, and business is about profit and cost, the humanities are about value. That is a vertex of the triangle we cannot afford to lose.

We are the only publication thats committed to covering every angle. We have an important contribution to make, one thats needed now more than ever, and we need your help to continue publishing throughout the pandemic. So please, make a donation.

Read the rest here:
Science, business and the humanities: CP Snow's 'Two Cultures' sixty years on - TheArticle

Posted in Genetic Engineering | Comments Off on Science, business and the humanities: CP Snow’s ‘Two Cultures’ sixty years on – TheArticle

FDA Warns About Stem Cell Therapies | FDA

Posted: October 5, 2021 at 8:08 pm

Espaol

Researchers hope stem cells will one day be effective in the treatment of many medical conditions and diseases. But unproven stem cell treatments can be unsafeso get all of the facts if youre considering any treatment.

Stem cells have been called everything from cure-alls to miracle treatments. But dont believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous proceduresand confirm whats really being offered before you consider any treatment.

The facts: Stem cell therapies may offer the potential to treat diseases or conditions for which few treatments exist. Sometimes called the bodys master cells, stem cells are the cells that develop into blood, brain, bones, and all of the bodys organs. They have the potential to repair, restore, replace, and regenerate cells, and could possibly be used to treat many medical conditions and diseases.

But the U.S. Food and Drug Administration is concerned that some patients seeking cures and remedies are vulnerable to stem cell treatments that are illegal and potentially harmful. And the FDA is increasing its oversight and enforcement to protect people from dishonest and unscrupulous stem cell clinics, while continuing to encourage innovation so that the medical industry can properly harness the potential of stem cell products.

To do your part to stay safe, make sure that any stem cell treatment you are considering is either:

And see the boxed section below for more advice.

The FDA has the authority to regulate stem cell products in the United States.

Today, doctors routinely use stem cells that come from bone marrow or blood in transplant procedures to treat patients with cancer and disorders of the blood and immune system.

With limited exceptions, investigational products must also go through a thorough FDA review process as investigators prepare to determine the safety and effectiveness of products in well-controlled human studies, called clinical trials. The FDA has reviewed many stem cell products for use in these studies.

As part of the FDAs review, investigators must show how each product will be manufactured so the FDA can make sure appropriate steps are being taken to help assure the products safety, purity, and strength (potency). The FDA also requires sufficient data from animal studies to help evaluate any potential risks associated with product use. (You can learn more about clinical trials on the FDAs website.)

That said, some clinics may inappropriately advertise stem cell clinical trials without submitting an IND. Some clinics also may falsely advertise that FDA review and approval of the stem cell therapy is unnecessary. But when clinical trials are not conducted under an IND, it means that the FDA has not reviewed the experimental therapy to help make sure it is reasonably safe. So be cautious about these treatments.

About FDA-approved Products Derived from Stem Cells

The only stem cell-based products that are FDA-approved for use in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood.

These products are approved for limited use in patients with disorders that affect the body system that is involved in the production of blood (called the hematopoietic system). These FDA-approved stem cell products are listed on the FDA website. Bone marrow also is used for these treatments but is generally not regulated by the FDA for this use.

All medical treatments have benefits and risks. But unproven stem cell therapies can be particularly unsafe.

For instance, attendees at a 2016 FDA public workshop discussed several cases of severe adverse events. One patient became blind due to an injection of stem cells into the eye. Another patient received a spinal cord injection that caused the growth of a spinal tumor.

Other potential safety concerns for unproven treatments include:

Note: Even if stem cells are your own cells, there are still safety risks such as those noted above. In addition, if cells are manipulated after removal, there is a risk of contamination of the cells.

When stem cell products are used in unapproved waysor when they are processed in ways that are more than minimally manipulated, which relates to the nature and degree of processingthe FDA may take (and has already taken) a variety of administrative and judicial actions, including criminal enforcement, depending on the violations involved.

In August 2017, the FDA announced increased enforcement of regulations and oversight of stem cell clinics. To learn more, see the statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA website.

And in March 2017, to further clarify the benefits and risks of stem cell therapy, the FDA published a perspective article in the New England Journal of Medicine.

The FDA will continue to help with the development and licensing of new stem cell therapies where the scientific evidence supports the products safety and effectiveness.

Know that the FDA plays a role in stem cell treatment oversight. You may be told that because these are your cells, the FDA does not need to review or approve the treatment. That is not true.

Stem cell products have the potential to treat many medical conditions and diseases. But for almost all of these products, it is not yet known whether the product has any benefitor if the product is safe to use.

If you're considering treatment in the United States:

If you're considering treatment in another country:

The rest is here:
FDA Warns About Stem Cell Therapies | FDA

Posted in Stem Cell Treatments | Comments Off on FDA Warns About Stem Cell Therapies | FDA

Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission – Digital Journal

Posted: October 5, 2021 at 8:07 pm

This umbilical cord blood bank encourages parents to get the best healthcare option for their children.

When Anja Health founder Kathryn Cross was 3 and her brother was 1, he was in a near-drowning accident. His physicians quickly diagnosed him with cerebral palsy, and her parents began searching for a treatment. When they discovered umbilical cord blood, the possibilities that the future held suddenly widened. Umbilical cord blood was increasingly being studied as a treatment for cerebral palsy via clinical trials. Its versatile stem cells were already FDA-approved to treat 85+ diseases, and approximately 1,300 ongoing clinical trials were examining other use cases. Research for cerebral palsy in particular was promising, but the Cross family was ultimately unable to find an umbilical cord blood stem cell match that could have acted as a treatment.

When the founder later lost her brother to cerebral palsy and pneumonia complications, she realized that there was not only a limited supply of life-changing stem cells, but there was also limited awareness. In that moment, Anja Health was born.

Anja Health is a preventative care brand that offers Anja Health Family Defense, Anja Health Family Defense Plus, and Anja Health Family Defense Bundle to collect stem cells from the umbilical cord blood, cord tissue, and placenta.

With stem cell treatments unique ability to grow and develop into almost any cell type in the body, it has earned a reputation for being one of the most sought-after medical solutions and is now at the forefront of a brighter future for medicine. With its proven track record of saving lives, many parents now consider collecting their babys umbilical cord blood to preserve it for future use.

Anja Health collects, cryopreserves, and safe-keeps samples in its New-Jersey-based AABB-accredited, FDA-approved partner facility. It also updates its clients (even after birth and collection) of the newest stem cell uses to illustrate how clients can use samples when a need arises.

Stem cell treatments from banked cord blood, tissue, and placenta stem cells can be wonderfully life-altering for those who suffer from different diseases, said Anja Health founder Kathryn Cross. Today, banking is not simply an insurance policy in the low-probability case that your child gets a disease. Rather, if someone has access to stem cells and they stay up to date with its use cases as they develop, they will use stem cells at some point in their life.

Visithttps://anjahealth.com/for more information about the company and its services.

About Anja Health

Anja Health is a preventative care brand that provides services for collecting and preserving stem cells. Anja aims to bring the revolutionary benefits of stem cell treatments to individuals, especially those who suffer from various diseases.

Media ContactCompany Name: AnjaContact Person: Kathryn CrossEmail: Send EmailCountry: United StatesWebsite: https://anjahealth.com/

See the original post here:
Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal

Posted in Stem Cell Treatments | Comments Off on Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission – Digital Journal

Kite’s Tecartus is First CAR T Therapy Approved for Adults with B-Cell ALL – Clinical OMICs News

Posted: October 5, 2021 at 8:07 pm

The FDA has granted approval for Kites Tecartus (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Tecartus is the first and only chimeric antigen receptor (CAR) T-cell therapy approved for adults (18 years and older) with ALL. The drug had received FDA Breakthrough Therapy Designation and a priority review for this indication.

In July 2020, the FDA approved Tecartus for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. Tecartus was the first cell-based gene therapy approved by the FDA for the treatment of MCL.

Tecartus has already transformed outcomes for adults living with mantle cell lymphoma, and we look forward to offering the hope for a cure to patients with ALL, said Christi Shaw, Chief Executive Officer of Kite, which is a Gilead company.

The drugs current approval for ALL is based on results from ZUMA-3, a global, multicenter, single-arm, open-label study in which 65% of the evaluable patients (n=54) achieved complete remission (CR) or CR with incomplete hematological recovery (CRi) at a median actual follow-up of 12.3 months. The duration of CR was estimated to exceed 12 months for more than half the patients. Among efficacy-evaluable patients, median duration of remission (DOR) was 13.6 months.

There were side effects. Among the patients treated with Tecartus at the target dose (n=78), Grade 3 or higher cytokine release syndrome (CRS) and neurologic events occurred in 26% and 35% of patients, respectively. Kite reports these side effects were generally well-managed.

Median overall survival (OS) from ALL is only approximately eight months with current standard-of-care treatments

Adults with ALL face a significantly poorer prognosis compared to children, and roughly half of all adults with B-ALL will relapse on currently available therapies, said Bijal Shah, MD, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Florida. We now have a new meaningful advancement in treatment for these patients. A single infusion of Tecartus has demonstrated durable responses, suggesting the potential for long-term remission and a new approach to care.

Adults with relapsed or refractory ALL often undergo multiple treatments including chemotherapy, targeted therapy, and stem cell transplant. Instead, CAR T-cell therapy works by harnessing a patients own immune system to fight cancer. With CAR T, the patients blood is drawn and the T cells are separated. Then the T cells are genetically engineered with a specific receptor that enables them to identify and attack cancer cells, and put back into the patients body.

Roughly half of all ALL cases actually occur in adults, and unlike pediatric ALL, adult ALL has historically had a poor prognosis, said Lee Greenberger, PhD, Chief Scientific Officer of The Leukemia & Lymphoma Society (LLS). Developing new therapies that would be life-changing for people with cancer has been a dream of LLS. We are proud to see the potential of CAR T realized for even more people with this approval for brexucabtagene autoleucel. Patients can accessTecartus through 109 authorized treatment centers across the US.

Tecartus is also currently under review in the European Union and United Kingdom for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.

View post:
Kite's Tecartus is First CAR T Therapy Approved for Adults with B-Cell ALL - Clinical OMICs News

Posted in Stem Cell Treatments | Comments Off on Kite’s Tecartus is First CAR T Therapy Approved for Adults with B-Cell ALL – Clinical OMICs News

StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa – WSAW

Posted: October 5, 2021 at 8:07 pm

StemExpress to use utilize the Thermo Fisher Accula rapid PCR testing system to provide event attendees with accurate results in 30 minutes.

Published: Oct. 5, 2021 at 2:33 PM CDT|Updated: 4 hours ago

SACRAMENTO, Calif., Oct. 5, 2021 /PRNewswire/ --StemExpress is proud to announce that they will be the official COVID-19 testing provider for 2021's Meeting on the Mesa, a hybrid event bringing together great minds in the cell and gene biotech sphere. It has partnered with Alliance for Regenerative Medicine to comply with the newly implemented California state COVID-19 vaccination and testing policy regarding gatherings with 1,000 or more attendees. This partnership will allow the vital in-person networking aspect of the event to commence while protecting the health and safety of participants and attendees.

In-person networking commences at the 2021 Cell and Gene Meeting on the Mesa with COVID-19 testing options provided by StemExpress.

As a leading global provider of human biospecimen products, StemExpress understands the incredible impact that Meeting on the Mesa has on the industry and has been a proud participant for many years. For over a decade, StemExpress has provided the cell and gene industry with vital research products and holds valued partnerships with many of this year's participants. As such, it understands the immense value that in-person networking provides and is excited to help bring this element back to the meeting safely and responsibly.

StemExpress has been a trusted provider of widescale COVID-19 testing solutions since early 2020 - providing testing for government agencies, public health departments, private sector organizations, and the public nationwide. For Meeting on the Mesa, StemExpress is offering convenient testing options for unvaccinated attendees and those traveling from outside of the country. Options will include take-home RT-PCR COVID Self-Testing Kits and on-site, rapid PCR testing for the duration of the event. The self-testing kit option allows attendees to test for COVID in the days leading up to the event for a seamless admission and the days following the event to confirm they haven't been exposed. The on-site rapid testing option utilizes the new Thermo Fisher Accula, offering in-person testing at the event with results in around 30 minutes. StemExpress is excited to bring these state-of-the-art COVID testing solutions to the frontlines of the Cell & Gene industry to allow for safe in-person connections.

The StemExpress partnership with Alliance for Regenerative Medicine seeks to empower the entire cell and gene industry with a long-awaited opportunity to return to traditional networking practices. It is well known that innovation doesn't exist in a vacuum - allowing great minds to come together is a sure way to spur scientific growth and advance cutting-edge research, giving hope for future cures.

Cell and Gene Meeting on the Mesa will take place October 12th, 2021, through October 14th, 2021, at Park Hyatt Aviara,7100 Aviara Resort Drive Carlsbad, CA 92011. To learn more about the event, please visit MeetingOnTheMesa.com.

For more information about COVID testing solutions for businesses and events, visit https://www.stemexpress.com/covid-19-testing/.

About StemExpress:

Founded in 2010 and headquartered in Sacramento, California, StemExpress is a leading global biospecimen provider of human primary cells, stem cells, bone marrow, cord blood, peripheral blood, and disease-state products. Its products are used for research and development, clinical trials, and commercial production of cell and gene therapies by academic, biotech, diagnostic, pharmaceutical, and contract research organizations (CRO's).

StemExpress has over a dozen global distribution partners and seven (7) brick-and-mortar cellular clinics in the United States, outfitted with GMP certified laboratories. StemExpress runs its own non-profit supporting STEM initiatives, college and high school internships, and women-led organizations. It is registered with the U.S. Food and Drug Administration (FDA) and is continuously expanding its network of healthcare partnerships, which currently includes over 50 hospitals in Europe and 3 US healthcare systems - encompassing 31 hospitals, 35 outpatient facilities, and over 200 individual practices and clinics.

StemExpress has been ranked by Inc. 500 as one of the fastest-growing companies in the U.S.

About the Alliance for Regenerative Medicine:

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 12-year history, ARM has become the voice of the sector, representing the interests of 400+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Media Contact: Anthony Tucker, atucker@stemexpress.com

View original content to download multimedia:

SOURCE StemExpress

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Originally posted here:
StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WSAW

Posted in California Stem Cells | Comments Off on StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa – WSAW

BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa – WWNY

Posted: October 5, 2021 at 8:07 pm

Published: Oct. 4, 2021 at 6:00 AM EDT

NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conferenceOctober 12-14, and October 19-20, 2021.

Dr. Lindborg's presentation highlights the expansion of Brainstorm's technology portfolio to include autologous and allogeneic product candidates, covering multiple neurological diseases. The most progressed clinical development program, which includes a completed phase 3 trial of NurOwn in ALS patients, remains the highest priority for Brainstorm. Brainstorm is committed to pursuing the best and most expeditious path forward to enable patients to access NurOwn.

Dr. Lindborg's presentation will be in the form of an on-demand webinar that will be available beginning October 12. Those who wish to listen to the presentation are required to registerhere. At the conclusion of the 2021 Cell & Gene Meeting on the Mesa, a copy of the presentation will also be available in the "Investors and Media" section of the BrainStorm website underEvents and Presentations.

About the 2021 Cell & Gene Meeting on the Mesa

The meeting will feature sessions and workshops covering a mix of commercialization topics related to the cell and gene therapy sector including the latest updates on market access and reimbursement schemes, international regulation harmonization, manufacturing and CMC challenges, investment opportunities for the sector, among others. There will be over 135 presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies.

The conference will be delivered in a hybrid format to allow for an in-person experience as well as a virtual participation option. The in-person conference will take place October 12-14 in Carlsbad, CA. Virtual registrants will have access to all content via livestream during program dates. Additionally, all content will be available on-demand within 24 hours of the live program time. Virtual partnering meetings will take place October 19-20 via Zoom.

About NurOwn

The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwntechnology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).

For more information, visit the company's website atwww.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future NurOwnmanufacturing and clinical development plans, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect,""likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwntreatment candidate, the initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwntreatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture, and commercialize the NurOwntreatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

ContactsInvestor Relations:Eric GoldsteinLifeSci Advisors, LLCPhone: +1 646.791.9729egoldstein@lifesciadvisors.com

Media:Paul TyahlaSmithSolvePhone: + 1.973.713.3768Paul.tyahla@smithsolve.com

Logo- https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content:

SOURCE Brainstorm Cell Therapeutics Inc

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

More here:
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - WWNY

Posted in California Stem Cells | Comments Off on BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa – WWNY

Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 – Taiwan News

Posted: October 5, 2021 at 7:57 pm

An extensive research report on the Hormone Replacement Therapy Market envisaged diligently by MarketResearch.Biz comprises a 360-degree view of the present market situation as well as its future growth survey. This report will offer you all the accurate data related to the different market bifurcations covering a crystal-clear idea on the Hormone Replacement Therapy market. In addition, we are literally promising you to give the perfect information on the distinct marketing angles and status over the upcoming duration of 2021-2030. There are some of the most important marketing aspects that are adequately boosting the growth of the worldwide market. They are gross margins, market penetrations, CAGR study, Porters 5 Force Model, descriptive and well-defined graphical representations, business strategies, etc.

A report comprising market current and future trends, market analyst opinions and perspectives, competitive scenario, and key regions from both regional and global aspects. This Global Hormone Replacement Therapy Market report offers an overview of the ongoing state of the market and forecasts of future progress. SWOT study is used to calculate strong market players performance and calculating their strengths and weaknesses. The report studied different factors, covering driving factors and challenges. Among its other features is the recognition of key players in the market and split study and forecasting. In addition to Hormone Replacement Therapy market new entrants, the study report helps them to estimates the market opportunity. Furthermore, the study focuses on the current issues, technical progress, and future opportunities that will influence the market. According to a study of upcoming trends, the global Hormone Replacement Therapy Market is projected to grow in the upcoming years.

Competitive Landscape with Key players:

Abbott Laboratories, Novartis, Pfizer Inc, Mylan Laboratories, Merck and Co, Novo Nordisk, Bayer Healthcare, Eli Lilly, Genentech

Hormone Replacement Therapy Market Taxonomy

Segmentation by Product: Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy.

Segmentation by Route of Administration: Oral, Parenteral, Transdermal, Others.

Segmentation by Type of Disease: Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Others.

Regional Outlook: The Hormone Replacement Therapy Market

The current study analyzes the Hormone Replacement Therapy Market thoroughly. Research is also conducted for Russia, China, the United States, Taiwan, Germany, the United Kingdom, Italy, Japan, South Korea, Canada, France, Mexico, and Southeast Asia. It is expected that North America, Europe, Asia-Pacific, Latin America, and the rest of the world have the largest prudence in the Hormone Replacement Therapy market world.

Among other things, this report calculates factors that contribute to regional growth, such as the environment, Hormone Replacement Therapy market economic progress, and social factors. In the analysis, regional production records, revenue information, and manufacturer data were studied globally. Revenue and volume projection consider regional differences.

This report offers understanding into the accompanying variables:

Understanding Business Sector Development: This research provides a far-reaching outlook of the items provided by the top influencing players in the global Hormone Replacement Therapy market.

Advancement of new items: Reports anatomize the most latest innovative turns of events, innovative business strategies, and item dispatches.

Evaluating the cutthroat scene: Comprehensive investigation of market systems, geographic introduction, and item fragments of the markets prominent players.

Advancement of new business sectors: An cumulative manual for developing business sectors. Various areas are inspected across topographies in this report.

Market Expansion: The complete overview of progress and interests in the worldwide Hormone Replacement Therapy market, like new items, undiscovered topographies, and current patterns.

Get a Sample Copy Of Hormone Replacement Therapy Market Research Report Here: https://marketresearch.biz/report/hormone-replacement-therapy-market/request-sample

Significant incorporation in the Hormone Replacement Therapy market report:

Impacts of the Covid 19 on progress status, temporarily and long haul.

A portion of the business crucial patterns.

Income, volume, and deals insights are included in this report.

Mentioned development possibilities.

Market and submarket development estimations.

Roundabout and direct deals channels: positives and negatives.

Hormone Replacement Therapy market sellers, dealers, and merchants are on the top of the list.

The labor force size and rebuild spaces of each organization are crucial subtleties.

Items and administrations are provided by the important players on the lookout.

Data from each organization in regard to its calculating model, deals volumes, net income, working interest, and a portion of the complete industry.

Itemized information on showcasing strategies, highlight the market, commercialization rates, just as other business-related information.

Table of Content

Section 1: Global Hormone Replacement Therapy Industry Outlook

Section 2: Global Economic Effect on Hormone Replacement Therapy Industry

Section 3: Global Market Competition by Industry Key Players

Section 4: Global Productions, Revenue (Value), with respect to the Regions

Section 5: Global Supplies (Production), Consumption, Export, Import, globally

Section 6: Global Productions, Revenue (Value), Current Trend, Price, Product Type

Section 7: Global Market Study, on the basis of Application

Section 8: Hormone Replacement Therapy Market Pricing Study

Section 9: Market Chain Analysis, Sourcing Strategy, and Downstream Buyers

Section 10: Business strategies and vital policies by Distributors/Suppliers/Traders

Section 11: Key Marketing Strategy Study, by Key Vendors

Section 12: Market Growth Driver Analysis and Their Impact Study

Section 13: Global Hormone Replacement Therapy Market Forecast

See the original post:
Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 - Taiwan News

Posted in Testosterone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 – Taiwan News

Global Osteoporosis Drug Market Size and Analysis, Services With Its Application and Access Type by Future Forecast 2021-2028 EcoChunk – EcoChunk

Posted: October 5, 2021 at 7:56 pm

DBMR has added another report named Global Osteoporosis Drug Market with information Tables for recorded and figure years addressed with Chats and Graphs spread through Pages with straightforward definite examination. The a-list report concentrates on broad assessment of the market development expectations and limitations. The systems range from new item dispatches, extensions, arrangements, joint endeavors, organizations, to acquisitions. This report includes profound information and data on what the markets definition, characterizations, applications, and commitment and furthermore clarifies the drivers and restrictions of the market which is gotten from SWOT investigation. Worldwide market examination report serves a great deal for the business and presents with answer for the hardest business questions. While making Global Osteoporosis Drug Market report, examination and investigation has been completed with one stage or the mix of a few stages relying on the business and customer necessities.

Market definition canvassed in the predominant Global Osteoporosis Drug Market advertising report investigates the market drivers that show factors causing ascend in the market development and market limitations which demonstrate the components causing fall in the market development. It helps clients or other market members to know about the issues they might confront while working in this market throughout a more extended timeframe. This statistical surveying report additionally concentrates on utilization of market, central participants included, deals, value, income and portion of the overall industry with volume and an incentive for every area. The greatness and straightforwardness proceeded in business research report makes acquire the trust and dependence of part organizations and clients.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-osteoporosis-drug-market&pm

Global Osteoporosis Drug Market By Type (Primary Osteoporosis and Secondary Osteoporosis), Therapy Type (Hormone replacement therapy and Bisphosphonate therapy), Treatment Type (Medication and Surgery), Mechanism of Action Type (Bisphosphonates, Selective Estrogen Receptor Modulators and Bone Resorption Inhibitors), Route of Administration Type (Oral, Intravenous, Subcutaneous), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends & Forecast to 2026

Global Osteoporosis Drug Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Osteoporosis Drug Industry

Increases prevalence of osteoporosis worldwideVulnerable aging population of menopause womenEmergence of drugs used in the treatment of celiac disease, inflammatory bowel disease, hyperthyroidism, chronic obstructive pulmonary disease (COPD) and bone marrow cancerAccelerates demand of novel therapies and newer development

Strategic collaboration and licensing deal between the companiesRising awareness about treatment and technological advancement is driving the growth of marketEffective treatment is either unavailable or unaffordable.Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the marketInadequate knowledge about osteoporosis in some developing countries

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-osteoporosis-drug-market

The titled segments and sub-section of the market are illuminated below:

By Type

Primary OsteoporosisPostmenopausal OsteoporosisSenile OsteoporosisIdiopathic OsteoporosisSecondary Osteoporosis

By Therapy Type

Hormone replacement therapy (HRT)Testosterone replacement therapyEstrogen therapyBisphosphonate therapy

By Treatment Type

MedicationCalcium and Vitamin D supplementsAntacidsSurgeryVertebroplastyKyphoplastyOthers

By Mechanism of Action Type

BisphosphonatesAlendronateIbandronateRisedronateZoledronicSelective Estrogen Receptor Modulators (SERMs)RaloxifeneBone Resorption InhibitorsDenosumab

By Route of Administration

OralIntravenousSubcutaneous

By End Users

HospitalsHomecareSpecialty ClinicsOthers

Top Players in the Market are:

Few of the major competitors currently working in the global osteoporosis drug market are Allergan, Amgen Inc, Astellas Pharma Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Teijin Pharma Limited, Stelis Biopharma, Radius Health, Inc, Pfizer Inc, Ono Pharmaceutical Co., Ltd, Novartis AG, Mochida Pharmaceutical Co., Ltd, Mereo BioPharma Group plc, Merck & Co., Inc, Gedeon Richter (UK) Ltd, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Cipla Inc, UCB SA, Teva Pharmaceutical Industries Ltd and among others.

Any query? Enquire Here For Discount Or Report Customization:@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-osteoporosis-drug-market&pm

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Osteoporosis Drug Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Osteoporosis Drug Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

See the rest here:
Global Osteoporosis Drug Market Size and Analysis, Services With Its Application and Access Type by Future Forecast 2021-2028 EcoChunk - EcoChunk

Posted in Testosterone Replacement Therapy | Comments Off on Global Osteoporosis Drug Market Size and Analysis, Services With Its Application and Access Type by Future Forecast 2021-2028 EcoChunk – EcoChunk

Fabulous menopause survey finds half suffer depression and loss of libido when going through The C… – The Sun

Posted: October 5, 2021 at 7:56 pm

THE menopause is often dismissed as just a few hot flushes.

But it can cause everything from brain fog and brittle bones to depression, insomnia, loss of libido, thinning hair and heart palpitations.

5

5

5

As part of our Fabulous Menopause Matters campaign, we lay bare its shocking toll to help women have the healthy menopause they deserve.

Exclusive research carried out for us revealed half of menopausal women suffered depression and mental health issues.

And 61 per cent of the 2,000 women aged 45-64 polled said they were given no medical help.

In our new campaign backed by MPs and celebrities we are calling for free HRT (Hormone Replacement Therapy) on the NHS for all women.

Labour MP Carolyn Harris is proposing a new law to waive prescription charges on HRT. The bill will go before Parliament on October 29.

We are also asking employers to create workplace policies to support menopausal women.

And we want to see action to bust the taboos surrounding the subject and to help women thrive.

TV host Davina McCall, 53, tackled the subject in a Channel 4 documentary earlier this year.

Hailing our fantastic campaign, the mum-of-three tells Fab Daily: Nobody talked about it when I was in my early 40s.

"I thought it was something that happened in your 50s. You got a couple of hot flushes and then you were through it.

Davina, an ambassador for The Menopause Charity adds: I had no idea about the importance of hormones and how much our body needs them.

We want to see action to bust the taboos surrounding the subject and to help women thrive

Every woman at 45 should go and speak to their doctor and talk about it. People dont understand the other symptoms.

In medical terms, a woman is menopausal 12 months after her last period, but symptoms can start many years beforehand a time called the perimenopause.

Along with the mental health issues, our research found 70 per cent of menopausal women experienced hot flushes, 62 per cent battled night sweats and 54 per cent had difficulty sleeping.

Meanwhile, 16 per cent said their brain fog was the most debilitating symptom.

Many of these symptoms can be cured by HRT, but a flawed 2002 study linking it to breast cancer left women scared to take it and doctors reluctant to prescribe it.

When it is offered, women still have to pay 9.35 per prescription and with people often needing more than one a month, many are unable to afford the potentially life-changing treatment.

70 per cent of menopausal women experienced hot flushes, 62 per cent battled night sweats and 54 per cent had difficulty sleeping

The result? Millions are left feeling abandoned and questioning their sanity.

When Kathryn Colas, 70, started experiencing rages and dark depressions two decades ago, she thought she was having a nervous breakdown.

And she found herself screaming at her husband of 25 years about anything from household chores to cooking.

Kathryn, from Uckfield, East Sussex, did not know it at the time, but she was in the grips of the menopause.

Over the next ten years, she would tell husband Antonio she wanted a divorce, walk away from the career she loved and question if she was losing her mind.

She says: I felt completely lost and questioned my own sanity. I was in such a dark place. I wondered if it would be best if I wasnt here at all.

The menopause can take a big toll on relationships and sex lives. Just over half (51 per cent) in our poll said it lowered their libido.

And 14 per cent said their relationship became strained. As Kathryns marriage with Antonio, 74, fell apart, she found herself retreating into her shell.

Like pregnancy, menopause is a time in a womans life when extra support at work is vital

She says: I couldnt find the words to express myself. My brain just couldnt find the words.

When a trip to celebrate their silver wedding anniversary in 2006 turned into one constant row, the couple, who have three grown-up children, decided to separate for a while.

It left Kathryn on the brink of suicide. Again, I questioned my own sanity, she says.

But it is not just relationships that suffer. More than a quarter of women said the menopause placed a strain on their work life and only 11 per cent said their employer was understanding.

Four per cent said the strain was so bad they had to quit their job.

What is the menopause and what age does it usually start?

Menopause is a natural part of ageing, which usually happens when a woman is between the age of 45 and 55.

In the UK, the average age for a woman to go through menopause is 51.

It occurs when oestrogen levels in the body start to decline.

During this time periods become less frequent or they can suddenly stop, and after menopause occurs women will be unable to become pregnant naturally.

Around one in 100 women experience menopause before the age of 40, and this is known as premature ovarian insufficiency or premature menopause.

Many celebrities have spoken out about their own experiences, including Lisa Snowdon, Davina McCall, Michelle Heaton and Zoe Hardman.

What are the symptoms?

Menopausal symptoms can start months or years before your periods stop, and can last until four years or longer after your last period.

Symptoms include:

Like pregnancy, menopause is a time in a womans life when extra support at work is vital.

Without it, talented employees are lost and the gender pay gap widens. Kathryn quit her job as a sales and marketing director for a hotel in Surrey.

I felt I couldnt cope with anything any more, she says.

I was used to balancing so many plates in the air and now they all came crashing down around me.

Having a major role running a hotel was the best job ever. I was good at it and I loved it. But suddenly I felt out of my depth.

Despite a catalogue of crippling symptoms, many women spend years suffering in silence

On one occasion, Kathryn flew into such a rage she swept everything off her desk. It was over nothing, she says. I just saw red. I wanted to smash everything.

"I didnt know what was going on. I began to research my symptoms the arguments at home, my lack of control at work.

I wrongly diagnosed myself with bipolar disorder. This is when I resigned and said I couldnt work.

Despite a catalogue of crippling symptoms, many women spend years suffering in silence.

Just 39 per cent polled have spoken to their GP or another specialist.

Fearing she was having a breakdown, Kathryn went to see her GP, who referred her to a psychiatrist.

But her symptoms were mistaken for depression and she was offered antidepressants instead of the HRT she needed.

It is a familiar story. Our research found 42 per cent of women were offered antidepressants or medication other than HRT. Of those, 25 per cent took the drugs on offer.

Kathryn declined and sought help from Professor John Studd, a retired obstetrics and gynaecology expert she met at a British Menopause Society event.

Through him she learned her mental health issues were related to hormones and it was part of the menopause.

Kathryn says: Like so many women, I had no idea how severe the impact could be.

Some specialists implied my experience was rare, but it isnt. Five years after she first started experiencing symptoms, Kathryn was finally offered HRT.

Our research found eight in ten who take HRT said it helped improve their lives and without any side-effects.

Working with experts, the Fabulous Menopause Matters campaign aims to help all women regardless of their age, income and background

Kathryn now takes progesterone vaginally as well as oestrogen and testosterone gel.

She reveals: The impact has been significant. I found my normal. I felt good on waking up. I felt creative.

As it began to have an impact on my mood, I realised that I loved Antonio, I always had. Thankfully, he forgave me and were still together 15 years on.

Fabulous GP Dr Zoe says that for most women with no previous family history of breast cancer, the benefits of HRT outweigh any risks.

Fabulous Menopause Matters

An estimated one in five of the UKs population are currently experiencing it.

Yet the menopause is still whispered in hush tones like its something to be embarrassed about.

The stigma attached to the transition means women have been suffering in silence for centuries.

The Sun are determined to change that, launching the Fabulous Menopause Matters campaign to give the taboo a long-awaited kick, and get women the support they need.

The campaign has three aims:

The campaign has been backed by a host of influential figures including Baroness Karren Brady CBE, celebrities Lisa Snowdon, Jane Moore, Michelle Heaton, Zoe Hardman, Saira Khan, Trisha Goddard, as well as Dr Louise Newson, Carolyn Harris MP, Jess Phillips MP, Caroline Nokes MP and Rachel Maclean MP.

Exclusive research commissioned by Fabulous, which surveyed 2,000 British women aged 45-65 who are going through or have been through the menopause, found that 49% of women suffered feelings of depression, while 7% felt suicidal while going through the menopause.

50% of respondents said there is not enough support out there for menopausal women, which is simply not good enough. Its time to change that.

And she advises: If your GP is reluctant to offer HRT, speak to another GP, or book an appointment with the practice nurse.

Another big issue women face is how the menopause affects their appearance and self-confidence. Our poll found 56 per cent gained weight, while 28 per cent noticed hair loss and 32 per cent had more facial hair.

Claire Hattrick, 54, a beauty therapist and blogger from Andover, Hants, who also runs blog 'Clipboard Claire', says she was left feeling unattractive.

The single mum to twins Abby and Beth, 23, tells Fab Daily: One of the biggest problems was joint pain.

"My knees were so bad people had to haul me up out of the car.

Our research found eight in ten who take HRT said it helped improve their lives and without any side-effects

I wasnt able to carry on with my normal gym routine and as a result I found myself battling the bulge, having put on a stone.

It was a struggle to leave the house as I hated my appearance. I lost eight years of my life. I felt washed-up . But it doesnt have to be this way. If women got support, there is life post-menopause.

Working with experts, the Fabulous Menopause Matters campaign aims to help all women regardless of their age, income and background.

By giving them the tools and access to medical care they need, the menopause scandal can be a thing of the past.

It is time to stop surviving and start thriving.

5

5

Visit link:
Fabulous menopause survey finds half suffer depression and loss of libido when going through The C... - The Sun

Posted in Testosterone Replacement Therapy | Comments Off on Fabulous menopause survey finds half suffer depression and loss of libido when going through The C… – The Sun

Page 656«..1020..655656657658..670680..»